Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01381315 · ClinicalTrials.gov registry record · Phase 2
Axillary Reverse Mapping
A Phase 2 study, sponsored by University of Kansas Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 210
- Enrollment target
NCT01381315 is a Phase 2 study that has completed, run by University of Kansas Medical Center. The registered enrollment target is 210 participants.
The verdict
NCT01381315, a Phase 2 study, has completed, sponsored by University of Kansas Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 210 participants
- Enrollment target
Study Summary
It has been hypothesized that the proximity of the anatomic locations of the arm lymphatic drainage system to the breast lymphatic system in the axilla put the arm lymphatics at risk for disruption during a sentinel lymph node biopsy (SLNB) and/or axillary lymph node dissection (ALND). Therefore, mapping the drainage of the arm in addition to the drainage of the breast during the procedure would potentially decrease the incidence of arm lymphatic disruption and subsequent development of lymphedema while providing adequate axillary breast nodes needed for staging.
Interventions
- PROCEDURE Injection of isotope
- PROCEDURE Axillary lymph node dissection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Start Date | 2009-09 |
| Est. Completion | 2016-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01381315
The ClinicalTrials.gov registry entry for NCT01381315 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 210 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Injection of isotope is the first listed.
NCT01381315 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01381315 about?
NCT01381315 is a clinical study titled "Axillary Reverse Mapping". It has been hypothesized that the proximity of the anatomic locations of the arm lymphatic drainage system to the breast lymphatic system in the axilla put the arm lymphatics at risk for disruption during a sentinel lymph node biopsy (SLNB) and/or axillary lymph node dissection (ALND). Therefore, ma...
What is the current status of trial NCT01381315?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 210 participants. The study started on 2009-09. Estimated completion is 2016-05.
What interventions are being tested in trial NCT01381315?
The interventions under investigation include: Injection of isotope (PROCEDURE), Axillary lymph node dissection (PROCEDURE).
Who is sponsoring clinical trial NCT01381315?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.